Mineralys Therapeutics (MLYS) Shares Outstanding (Weighted Average) (2022 - 2026)

Mineralys Therapeutics has disclosed Shares Outstanding (Weighted Average) across 5 years of filings, most recently posting $82.8 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $82.8 million, up 55.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.8 million (up 55.81% YoY), and the FY2025 annual result was $67.7 million, up 39.38% from the prior year.
• Shares Outstanding (Weighted Average) came in at $82.8 million for Q1 2026 at Mineralys Therapeutics, up from $67.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $82.8 million in Q1 2026 to a low of $5.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $44.9 million (2024), against an average of $39.8 million.
• Across the five-year window, Shares Outstanding (Weighted Average) surged 600.33% in 2023 and advanced 18.4% in 2025, its largest moves.
• Mineralys Therapeutics' Shares Outstanding (Weighted Average) stood at $5.2 million in 2022, then soared by 600.33% to $36.2 million in 2023, then soared by 34.13% to $48.5 million in 2024, then jumped by 39.38% to $67.7 million in 2025, then grew by 22.43% to $82.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $82.8 million (Q1 2026), $67.7 million (Q4 2025), and $70.6 million (Q3 2025), per Business Quant data.